OSIRIS THERAPEUTICS,INC. (OTCMKTS:OSIR) Files An 8-K Changes in Registrant’s Certifying AccountantItem 4.01. Changes in Registrant’s Certifying Accountant.
As previously announced, on December 17, 2015, following the conclusion of a competitive process managed by the Audit Committee of the Board of Directors of Osiris Therapeutics, Inc. (the “Company”), the Company selected Ernst & Young LLP (“Ernst & Young”) to serve as its independent registered public accounting firm for the year ended December 31, 2015. On May 16, 2017, Ernst & Young completed its standard client acceptance procedures and was formally engaged by the Company as its independent registered public accounting firm.
During the years ended December 31, 2016 and December 31, 2015 and through May 16, 2017, neither the Company, nor anyone on its behalf, has consulted Ernst & Young with respect to (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report was provided to the Company nor oral advice was provided to the Company that Ernst & Young concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).
